Abstract 1564
Background
Geriatric assessments (GA) allow evaluation of individual global health status and treatment optimisation. This real-life study complements the knowledge on chemotherapy (CT) and bevacizumab usage in elderly with mCRC focussing the impact of geriatric screening and GA on TD, PFS and severe toxicity.
Methods
This study included 252 Belgian mCRC patients ≥ 70 years receiving CT with or without bevacizumab. Eastern Cooperative Oncology Group (ECOG), geriatric screening with G8 and Flemish Triage Risk Screening Tool (fTRST), as well as GA including activities of daily living (ADL), instrumental activities of daily living (IADL), Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Mini Nutritional Assessment (MNA), Charlson Comorbidity Index (CCI), and Mobility-Tiredness Test (Mob-T) was performed in all patients at baseline. For correlations with the different screening and GA components, logrank tests (for TD and PFS), Wilcoxon or Student t-tests (for severe toxicity) and multivariate analyses were used. Additionally, a subgroup analysis excluding patients with ECOG ≥ 2 at baseline was performed.
Results
Median TD (95% CI) was 5.5m (5.1-6.2) in the total safety population. In univariate analysis, ECOG > 1, which was only 14.6% of patients, and MNA were the only baseline parameters significantly associated with TD (p = 0.0006 and p = 0.0162, respectively), while G8 showed a trend (p = 0.0607). Significant correlations were observed for PFS vs. ECOG (p
Conclusions
In older mCRC patients, ECOG is a strong predictive marker for treatment duration and PFS, mainly driven by patients with ECOG ≥ 2. In the large group of patients with ECOG ≤ 1, MNA is a predictive marker for PFS.
Clinical trial identification
NCT01676922
Legal entity responsible for the study
Roche NV/SA Belgium
Funding
Roche NV/SA Belgium
Disclosure
All authors have declared no conflicts of interest.